A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, dry eye, retinal diseases and other diseases of the eye
News HighlightsAerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s... Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated ... Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial R...
Jul 2, 4:00 PM ET
52 - WEEK LOW/HIGH